Shanghai First Peoples Hospital

Shanghai, China

Shanghai First Peoples Hospital

Shanghai, China
SEARCH FILTERS
Time filter
Source Type

Patent
Shanghai First Peoples Hospital | Date: 2014-08-13

Disclosed are a low molecular polypeptide for preventing and treating inflammation, a preparation method and the use thereof and a pharmaceutical composition containing the polypeptide, wherein the polypeptide can penetrate the eye tissue barrier, can maintain a high concentration in neutral tears, aqueous humour and vitreous humour, and can be used to treat inflammation.


Lin J.,Shanghai First Peoples Hospital
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences | Year: 2013

To evaluate the efficacy and safety of combining reduction plating with reamed intramedullary nailing for segmental fractures of proximal-middle tibia. From June 2007 to October 2011, 31 patients with segmental fractures of proximal-middle tibia were admitted. There were 18 males and 13 females, with an average age of 45.2 years (range: 23-77 years), of whom, 9 were Gustilo I type open fractures and 22 were close fractures. All the patients were treated with assisting plate combined with reamed intramedullary nailing. The operation was performed averagely 35 h (range: 16-72 h) after injury. During the post-operation follow-up radiographic evaluation, the range of knee joint, and Johner-Wruhs scores were measured. All the patients were followed-up for 18.5 months (range: 17-24 months). No wound infection or osteofascial compartment syndrome happened. All the fractures healed after 5.1 months (range: 4-6 months). The proximal and distal fracture sites healed simultaneously. No malunion was found. In the last follow-up, the mean range of knee joint was 9°-0°-127°, and according to Johner-Wruhs scores, 19 were excellent, 10 good, and 2 fair. Assisting plate with reamed intramedullary nailing is a safe and effective alternative choice for segmental fractures of proximal-middle tibia, which can ease the difficulty of the procedure, improve the quantity of reduction and enhance the stability of the hardware.


Patent
Shanghai First Peoples Hospital | Date: 2012-10-29

Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.


Patent
Shanghai First Peoples Hospital | Date: 2013-06-05

Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.


Patent
Shanghai First Peoples Hospital | Date: 2011-06-22

The utility model relates to medical apparatus, and in particular to a rigid/flexible adjustable ureteroscope which includes a body, an operation shank and a rigid/flexible adjustment support rod. A rigidity adjustment key controls the rigid/flexible adjustment support rod to be movable freely in the body so that the rigid/flexible adjustment support rod channel. Movement of the rigid/flexible adjustment support rod makes a part of the endoscope becomes rigid so as to have adequate rigidity to overcome resistance, avoiding the needs of hard sheath while entering a uterer. A front part of the endoscope may become from rigid to flexible by movement of the support rod, and the flexible front part may vary in length to accomplish the operation flexibly. The support rod is able to be movable or be drawn out from a support rod channel to serve the support rod channel as a work channel. By adjustment of sizes, a rigid/flexible adjustment fibronephorscope is provided, and alternatively, a rigid/flexible adjustment fiber urethra cystoscope is provided. Compared with the prior art, the utility model overcomes defects of various urethra cystoscopes, raises surgical efficacy and economic merits, avoids hurt to tissues, and reduces apparatus acquisition cost.


Patent
Shanghai First Peoples Hospital | Date: 2011-07-01

Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.


The present invention provides a polypeptide that is rich in leucine and used for preventing and restraining inflammation, and an application of same. The present invention further provides a method for preparing the polypeptide and a pharmaceutical composition containing the polypeptide. The advantage of the polypeptide comprises: small molecular weight, so as to permeate various eye tissue barriers; high water solubility, so as to have high dissolubility in neutral tears, aqueous humor and vitreous humor; and simple synthesis, so as to have a low preparation cost.


Patent
Shanghai First Peoples Hospital | Date: 2016-07-06

Disclosed are a low molecular polypeptide for preventing and treating inflammation, a preparation method and the use thereof and a pharmaceutical composition containing the polypeptide, wherein the polypeptide can penetrate the eye tissue barrier, can maintain a high concentration in neutral tears, aqueous humour and vitreous humour, and can be used to treat inflammation.


Patent
Shanghai First Peoples Hospital | Date: 2014-09-03

Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.


Patent
Shanghai First Peoples Hospital and Xu | Date: 2015-04-01

The present invention provides a polypeptide that is rich in leucine and used for preventing and restraining inflammation, and an application of same. The present invention further provides a method for preparing the polypeptide and a pharmaceutical composition containing the polypeptide. The advantage of the polypeptide comprises: small molecular weight, so as to permeate various eye tissue barriers; high water solubility, so as to have high dissolubility in neutral tears, aqueous humor and vitreous humor; and simple synthesis, so as to have a low preparation cost.

Loading Shanghai First Peoples Hospital collaborators
Loading Shanghai First Peoples Hospital collaborators